“Vertex’s willingness to drop VX-961 based on those variables reflects a belief that safety and efficacy are “table stakes--支柱” in pain. To succeed, Vertex is looking for “a molecule with the perfect PK” for the indication. That search is underpinned by an understanding of how pain...
3、https://www.orion.fi/en/Orion-group/media/press-releases/2022/orion-enters-into-exclusive-agreement-with-jemincare-for-novel-non-opioid-drug-candidate-for-the-treatment-of-pain/?epieditmode=true. 4、https://news.vrtx.com/news-r...
Jones J, Correll DJ, Lechner SM, et al. Selective Inhibition of Na1.8 with VX-548 for Acute Pain.N Engl J Med. doi:10.1056/NEJMoa2209870. 『梧桐医学』是由麻醉学(包含疼痛方向)本科、硕士、博士、博后以及刚工作的年轻医生组建的学习型...
In addition, the FDA has granted VX-548 Breakthrough Therapy Designation for the treatment of moderate-to-severe acute pain. The Phase 3 program will include two randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VX-548 for moderate to severe a...
–Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter – –Successful completion of end-of-phase 2 FDA meeting for pain associated with diabetic peripheral neuropathy (DPN); Phase 3...
–Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and bunionectomy randomized controlled trials –– Treatment
30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, ...
for the design of low MW blockers for the treatment of chronic pain. The NAV1.8 channel is highly expressed by small primary sensory neuronsand is closely related to the occurrence and development of various types of pain, such as inflammatory pain, neuropathic pain, and inflammatory pain. ...
This is likely related to a failure in proving the efficacy of alternative analgesics in clinical trials, despite strong evidence supporting the potential for effective analgesia through in vitro studies. While NaV1.7 and NaV1.8 channels have shown to be key components of pain perception, studies ...
[2] Jones, Jim et al. “Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.” The New England journal of medicine vol. 389,5 (2023): 393-405. doi:10.1056/NEJMoa2209870 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦...